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Abstract
Fungi, such as Candida spp., are commonly found on the skin and at mucosal surfaces. Yet, they rarely cause invasive
infections in immunocompetent individuals, an observation reflecting the ability of our innate immune system to control
potentially invasive microbes found at biological boundaries. Antimicrobial proteins and peptides are becoming
increasingly recognized as important effectors of innate immunity. This is illustrated further by the present investigation,
demonstrating a novel antifungal role of histidine-rich glycoprotein (HRG), an abundant and multimodular plasma protein.
HRG bound to Candida cells, and induced breaks in the cell walls of the organisms. Correspondingly, HRG preferentially
lysed ergosterol-containing liposomes but not cholesterol-containing ones, indicating a specificity for fungal versus other
types of eukaryotic membranes. Both antifungal and membrane-rupturing activities of HRG were enhanced at low pH, and
mapped to the histidine-rich region of the protein. Ex vivo, HRG-containing plasma as well as fibrin clots exerted antifungal
effects. In vivo, Hrg
2/2 mice were susceptible to infection by C. albicans, in contrast to wild-type mice, which were highly
resistant to infection. The results demonstrate a key and previously unknown antifungal role of HRG in innate immunity.
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Introduction
The innate immune system, based on antimicrobial peptides
(AMP) and proteins, provides a first line of defence against
invading microbes [1–3]. At present, over 880 different AMPs
have been identified in eukaryotes (www.bbcm.univ.trieste.it/
,tossi/pag5.htm). During recent years it has become increasingly
evident that many AMPs, such as defensins and cathelicidins, are
multifunctional, also mediating chemotaxis, apoptosis, and
angiogenesis [4–6]. Conversely, molecules previously not consid-
ered as AMPs, including proinflammatory and chemotactic
chemokines [7], neuropeptides [8], peptide hormones [9,10], the
anaphylatoxin peptide C3a [11,12], growth factors [13] and
kininogen-derived peptides [14–17] have recently been found to
exert antibacterial activities.
Histidine-rich glycoprotein (HRG) is a plasma protein which
was first isolated in 1972 by Heimburger et al. [18,19]. The protein
is present in human plasma at 1.5–2 mM, but the local
concentration when HRG is released from activated platelets is
likely to be higher [20–22]. It is a type 3 cystatin family protein
[23], along with a-2-HS-glycoprotein/fetuin-A, fetuin-B and
kininogen, and is found in vertebrates as well as in some
invertebrates. The structure contains two cystatin-like domains, a
central histidine-rich region (HRR) with highly conserved
GHHPH tandem repeats flanked by proline-rich regions, and a
C-terminal region [20]. This modular structure of HRG facilitates
multiple interactions, involving ligands such as heparin, plasmin-
ogen, fibrinogen, thrombospondin, heme, IgG, FccR, and C1q.
Due to its high content of histidine residues (,13%), which are
concentrated to the HRR, HRG can acquire a positive net charge
either by incorporation of Zn
2+, or by protonation of histidine
residues at acidic conditions [20]. In this context it has been
proposed that HRG acts as a pH and Zn
2+ sensor, providing a
mechanism for regulating the various activities of HRG [24].
HRG has recently been ascribed antiangiogenic [25] effects in vitro,
as well as antitumor [26] effects in vivo. Recent studies on Hrg
2/2
mice furthermore suggest that HRG plays a role as both an
anticoagulant and an antifibrinolytic modifier, and may regulate
platelet function in vivo [22].
Previous work has also demonstrated that HRG exert direct
antibacterial activities in vitro which are dependent on Zn
2+and pH
[27]. However, as many cationic proteins and peptide sequences
display antimicrobial properties in vitro, the ultimate role(s) of
HRG in innate immunity in vivo still remained unresolved. During
the course of our studies, we observed that HRG had a significant
activity against Candida. Candida, an eukaryote, is present as a
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cause life-threatening sepsis in immunocompromised individuals it
seldom causes invasive disease in immunologically normal
individuals [28]. We therefore speculated that HRG could
constitute a natural defence against Candida infections. In the
present study we show, using a combination of microbiological,
biochemical, and biophysical methods, that HRG exerts a potent
antifungal activity particularly at low pH, which is mediated via its
HRR, and targets ergosterol-rich membrane structures such as
those of Candida. In mouse infection models, HRG protects against
systemic infection by Candida, indicating a previously undisclosed
antifungal role of HRG in innate immunity.
Results
Antifungal activity of HRG and binding to Candida cells
In order to assess possible antifungal effects of HRG, we tested
the activity of the protein against various Candida isolates. HRG
was shown to be antifungal against C. parapsilosis at normal pH
(10 mM Tris, pH 7.4), and the activity was significantly increased
in low pH buffer (10 mM MES, pH 5.5) (Figure 1A). It is well-
known that activities of AMPs and antimicrobial proteins are
dependent of the microenvironment. For example, various
chemokines, defensins, LL-37 as well as heparin binding protein
are partly, or completely, antagonized by high salt conditions or
the presence of plasma proteins in vitro [27,29,30]. Therefore, the
influence of salt was tested. The results showed that HRG partially
retained antifungal activity at physiological Cl
2 levels (0.1 M) but
only at low pH (Figure 1B). The antifungal activity against C.
parapsilosis was both time- and dose-dependent (Figure 1C). In
subsequent experiments various Candida strains (C. parapsilosis, C.
albicans, C. glabrata and C. krusei) were incubated with HRG (at 3
mM) at neutral as well as low pH. Figure 1D demonstrates, in line
with the above experiments, that HRG is particularly active at low
pH. Thus, C. parapsilosis, C. albicans and C. krusei were all nearly
completely killed by HRG at low pH, whereas C. glabrata exhibited
a partial resistance at this concentration of HRG, the latter in
analogy to C. glabrata displaying some resistance against histatin 5
[31]. Next, to investigate the binding of HRG to fungi, C.
papapsilosis was incubated with HRG at low pH, washed, and
analysed by immunoblotting. Since previous results indicated that
the HRR of HRG, which binds heparin/heparan sulfate, mediates
antibacterial effects [27], heparin was added for competition of
binding to Candida. Figure 1E shows that HRG was able to bind to
the fungal cells and that the binding was partially inhibited by an
excess of heparin. This finding is compatible with the observation
that heparin completely blocks the antifungal effect of HRG
(Figure S1). As demonstrated by flow cytometry, HRG bound to
C. parapsilosis at neutral pH, and the binding was significantly
increased at pH 5.5 (Figure 1F), results compatible with the fungal
killing assays (Figure 1A). In summary, therefore, the results
demonstrate that the antifungal actions of HRG were pH-
dependent and likely mediated via the heparin-binding region of
the protein.
Membrane-permeabilizing effects of HRG
Many AMPs kill microbes by membrane lysis, while others may
translocate through membranes and subsequently interact with
intracellular targets, such as DNA and mitochondria, all eventually
resulting in microbial killing [32,33]. Considering the antifungal
effects and the binding to Candida cells, it was of interest to further
study the possible mode of action for HRG on Candida. Electron
microscopy demonstrated that HRG caused membrane breaks in
Candida cells and release of cytoplasmic components (Figure 2A),
effects particularly noted at low pH, where significant extracellular
material was detected. The effects were similar to those observed
after treatment with the ‘‘classical’’ human AMP LL-37
(Figure 2A). These data suggest that HRG acts on fungal
membranes, however they do not demonstrate the exact
mechanistic events, as secondary metabolic effects on fungi also
may trigger death and membrane destabilization. Therefore, the
impermeant dye FITC was used to assess permeabilisation. The
results showed that HRG indeed was able to permeabilise Candida
membranes (Figure 2B). In line with previous antifungal and
binding experiments (see Figure 1A and 1F), the permeabilisation
was most apparent at low pH.
These results were further substantiated by the use of a liposome
model to assessmembrane permeabilisation.Incorrespondencewith
the effects of HRG on Candida, HRG caused liposome leakage.
Compatible with the pH sensitivity observed for HRG, the molecule
preferably disrupted ergosterol-containing liposomes at pH 6.0
when compared with pH 7.4 (Figure 2C, left panel). Notably,
ergosterol-containing liposomes, mimicking fungal membranes,
were more sensitive than cholesterol-containing ones, mimicking
mammalian membranes (Figure 2C, right panel). These results are
in agreement with numerous previous findings on the membrane-
stabilizing effects of cholesterol [34], as well as the findings that
ergosterol induce less membrane stability in phospholipids than
cholesterol [35]. At lower pH, protonation of histidine groups (pKa
for the isolated histidine group is approximately 6.5), effectively
increases the net charge density of HRG, thus the observed effects
are compatible with findings previously reported for histidine-
containing consensus peptides and histidine-rich endogenous
peptides [36,37]. Also noteworthy is that HRG did not display any
majorconformationalchangeseitheratlowpH,orinthe presenceof
fungal mannan (Figure 2D) or ergosterol-containing phospholipid
liposomes (not shown). Hence, large-scale conformational changes
appear not to be critical for the antifungal action of HRG. Taken
together,thecombinationofelectronmicroscopy,FITC-studies,and
liposome data demonstrates that HRG acts at least in part through
membrane disruption, although it is possible that additional
intracellular effects of HRG may also contribute to fungal death. It
is also notable that the observed effects were most marked and
consistent at low pH. At neutral pH, binding (Figure 1B), as well as
Author Summary
It has been estimated that humans contain about 1 kg of
microbes, an observation that reflects our coexistence with
colonizing microbes such as bacteria and fungi. The fungal
species Candida is present as a commensal at mucosal
surfaces and on skin. Although it may cause life-
threatening infections, such as sepsis, particularly in
immunocompromised individuals, it seldom causes dis-
ease in normal individuals. In order to control our
microbial flora, humans as well as virtually all life forms
are armoured with various proteins and peptides that
comprise integral parts of our innate immune system. Here
we describe a new component in this system; histidine-rich
glycoprotein (HRG), an abundant plasma protein. We
show, using a combination of microbiological, biochemi-
cal, and biophysical methods, that HRG exerts a potent
antifungal activity, which is mediated via a histidine-rich
region of the protein, and targets ergosterol-rich mem-
brane structures such as those of Candida. HRG killed
Candida both in plasma as well as when incorporated into
fibrin clots. In mouse infection models, HRG was protective
against systemic infection by Candida, indicating a novel
antifungal role of HRG in innate immunity.
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observations reflected the diminished antifungal effects at pH 7.4
(Figure 1A and 1D).
Antifungal regions of HRG
In order to explore the structure-function relationships of epitopes
of HRG, overlapping peptide sequences comprising 20mers
(Figure 3A and Table S1) were synthesized and screened, at both
neutral and acidic pH, for antifungal activities against C. parapsilosis
as well as C. albicans. The experiments identified several antifungal
regions.Inparticularpeptidesno.20–24and26,spanningtheHRR,
displayed a significant antifungal activity against both Candida strains
at low pH (Figure 3B). There was a clear correlation with net charge
(at the respective pH) of the various peptide regions and their
observed antifungal activity (Figure S2). Although intuitively
apparent (Figure 3B), the analysis furthermore showed that peptides
derived from the HRR were (with the exception of the K and R-rich
peptide no. 27) characterized by an increase in net charge at low pH
(Table S1 and Figure S2).
In order to further study the importance of the HRR we
investigated the activity of recombinant HRG (rHRG) and a
truncated version (rHRG1-240), lacking the HRR and C-terminal
domain. In contrast to full-length rHRG, truncated rHRG (0.6
mM) displayed no activity at pH 5.5 against Candida (Figure 3C).
Taken together, considering the well-known heparin binding
capacity of HRR, its pH dependence, as well as the absence of
antifungal activity of rHRG1-240, it was logical to focus on the
HRR of HRG in the subsequent studies of antifungal activity.
The HRR contains 12 tandem repeats of fiveconsensus sequences
of amino acids, GHHPH [20], a motif highly conserved among
various vertebrate species [27]. To examine the activity of this
sequence motif further, a 20-mer peptide (GHHPH)4 [16,27] was
chosen for further studies. Similar to intact HRG, GHH20 was
antifungal againstC.parapsilosis and C.albicans,pa rt ic ul ar lyatlo wpH
(Figure 4A). As demonstrated by FACS analysis, Tetramethyl-6-
Carboxyrhodamine (TAMRA)-labeled GHH20 peptide bound to C.
parapsilosis, and in correspondence with the antifungal data, the
binding was stronger at pH 5.5 when compared to neutral pH
(Figure 4B). As illustrated by fluorescence microscopy, TAMRA-
labeled GHH20 showed a significant binding to Candida at pH 5.5
(Figure 4C). As with the HRG holoprotein, heparin abolished the
binding, reflecting the heparin-binding capacity of this region of the
HRR [27]. Also in line with the above experiments on fungi,
GHH20 preferably disrupted liposomes at pH 6.0, with no
significant activity at pH 7.4 (Figure 4D). The GHH20 peptide
caused liposome leakage within a few hundred seconds (not shown),
Figure 1. Antifungal activity and binding of HRG to Candida. (A) Antifungal activity of HRG. C. parapsilosis ATCC 90018 (1610
5 cfu) was
incubated with purified human HRG at concentrations ranging from 0.03 to 6 mM for 2 hours in 10 mM Tris, pH 7.4 (N) or 10 mM MES, pH 5.5 (#),
plated and the number of cfu determined (n=6). (B) Antifungal effects of HRG in salt. C. parapsilosis ATCC 90018 (1610
5 cfu) was incubated with 6
mM HRG for 2 hours in 10 mM MES, pH 5.5 containing 0, 25, 50, 100 or 150 mM NaCl, plated and the number of cfu was determined. (C) Killing
kinetics. 0.3 or 3 mM HRG were incubated with 1610
5 cfu C. parapsilosis ATCC 90018 for 0, 5, 15, 30, 60 or 120 minutes in 10 mM Tris, pH 7.4 (N)o r
10 mM MES, pH 5.5 (#), plated and the number of cfu determined. (D) Antifungal activity of HRG against different strains of Candida. 3 mM HRG were
incubated with 1610
5 cfu C. parapsilosis ATCC 90018 or BD 17837, C. albicans ATCC 90028 or BD 1060, C. glabrata ATCC 90030 or C. krusei ATCC 6258
in 10 mM Tris, pH 7.4 (black bars) or 10 mM MES, pH 5.5 (white bars) for 2 hours, plated and number of cfu determined (n=6). (E) Binding of HRG to
fungi. C. parapsilosis (1610
5 cfu) was incubated with HRG (0.6 mM) in 10 mM MES, pH 5.5. For inhibition studies, heparin (50 mg/ml) was added.
Samples were centrifuged and the pellet and supernatants were extracted and run on 8% SDS-PAGE under reducing conditions. HRG was detected
by western and immunoblotting using polyclonal antibodies against GHH20. Purified HRG was used as a positive control (labeled C). (F) Flow
cytometry analysis of binding of HRG to fungal membranes. C. parapsilosis (5610
7 cfu) were incubated with FITC-labeled HRG in 10 mM Tris pH 7.4 or
10 mM MES pH 5.5.
doi:10.1371/journal.ppat.1000116.g001
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leakage (Figure 2B), likely a manifestation of the much higher
molecular weight of the holoprotein. Again as with intact HRG, CD
spectroscopy showed that GHH20 displayed no major conforma-
tional changes associated with the histidine protonation at low pH,
nor on interaction with phospholipid liposomes or mannan (not
shown). Taken together, the GHH20 peptide showed similar
characteristics as the holoprotein HRG with respect to activity,
binding, and membrane permeabilisation.
HRG is found in biological fluids and is active in plasma
and in fibrin clots
In order to investigate the functional relevance of the above in vitro
activities, we first tested the role of HRG against fungi in relevant
physiological ‘‘settings’’ ex vivo. Initial results showed that HRG was
detected in blood fractions (plasma, serum) and in platelets, also in
wound fluid from acute wounds, and chronic leg ulcers (Figure 5A).
The latter wound type is characterized by unregulated and excessive
proteinase activity leading to degradation of many plasma proteins
[38,39]. However, compared with plasma and serum HRG, the
molecule was not fragmented in this chronic wound fluid fraction
(Figure 5A). The protein was also detected in fibrin clots (Figure 5A)
but not present in seminal plasma. It is of note that the molecule
migrated aberrantly in the used gel systems; relative 55–60 kDa in
8% gels (Tris-Glycine) and 45–50 kDa in 16.5 gels (Tris-Tricine).
Identical serum and plasma preparations of HRG were used in the
two gel systems, and recombinant HRG showed the same
anomalous migration (not shown). In addition to its presence in
plasma and other biological fluids, HRG occurs at significant levels
in, and binds avidly to, fibrin clots [40]. Coagulation was initiated in
normal and HRG-deficient human plasma in the presence of FITC-
labeled HRG (Figure 5B). FITC-labeled HRG bound to clots
derived from HRG-deficient plasma, and notably, it appeared to be
present at clot boundaries, suggesting that it may ‘‘coat’’ the clot
surfaces. In clots from normal plasma, no staining was seen,
indicative of an inhibition of binding of FITC-HRG by the excess of
endogenous HRG (,150 mg/ml). Clots, physiologically important
‘‘barriers’’, formed during hemostasis and infection, could thus
constitute a unique milieu with high levels of surface-immobilized
Figure 2. HRG induces membrane permeabilisation of Candida cells as well as liposomes. (A) Negative staining and electron microscopy
analysis of C. parapsilosis exposed to HRG. C. parapsilosis ATCC 90018 were incubated in the absence of HRG in 10 mM Tris, pH 7.4 or 10 mM MES,
pH 5.5. These fungi did not exhibit signs of membrane perturbations. In contrast, when treated with 10 mM HRG in 10 mM Tris, pH 7.4 or 10 mM MES,
pH 5.5 membrane damage, blebbing and ejection of cytoplasmic components was observed. Fungi treated with 10 mM LL-37 was used as a positive
control for membrane damage. The scale bar corresponds to 2 mm. (B) Fungal viability after incubation with HRG and LL-37. C. albicans ATCC 90028
were incubated with 10 mM HRG or LL-37 in either 10 mM Tris, pH 7.4 (left panel) or 10 mM MES, pH 5.5 (right panel). The left images in each row are
Nomarski Differential Interference Contrast images, whereas the right images show FITC fluorescence of fungi. (C) Effects of 1 mM HRG on liposome
permeability. Left panel. Increase in HRG-induced permeabilization of ergosterol-containing liposomes is detected at pH 6.0. Right panel. Increased
HRG-induced lysis of (at pH 7.4) ergosterol containing liposomes. (D) CD spectroscopy of HRG under different conditions. CD spectra for 0.25 mM HRG
in buffer and in presence of S. cerevisiae mannan are presented.
doi:10.1371/journal.ppat.1000116.g002
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presence of HRG could reduce the growth of Candida in plasma.
Firstly,thegrowth of C.parapsilosiswasinvestigatedin normalhuman
plasma and in plasma depleted of HRG. The results showed that C.
parapsilosis multiplied significantly faster in HRG-depleted human
plasma (Figure 5C). Analogous results on fungal growth were
observed using plasma from mice deficient in HRG (data not
shown). It is of note that these results do not exclude the possibility
that other antifungal mechanisms may be involved, such as those
dependent of complement activation. Furthermore, although the
total protein levels (as determined by the Bradford method) and
contents (as assessed bySDS-PAGEon 8% gels, not shown)werethe
same in depleted plasma (51.0+/21.2 g/l) when compared with
control plasma (51.7+/23.3 g/l), it cannot be excluded that
additional changes of low abundance proteins, induced by passage
over Ni-NTA agarose could affect Candida growth. Nevertheless, the
observation that similar results were obtained with the mice plasmas
points at HRG as the main factor responsible for the partial growth
inhibition noted. Furthermore, as demonstrated in Figure 5D, fibrin
clots derived from plasma of HRG deficient mice were significantly
more prone to infection by C. parapsilosis than clots from wild-type
mice, and similar results were obtained with human plasma depleted
of HRG when compared with normal plasma (not shown). The
observation that clots devoid of HRG showed detectable, although
reduced,antifungalactivity(Figure5D)suggest theexistenceof other
yet unidentified factors in clots also mediating fungal killing.
Nevertheless, the results indicate that HRG contributes to antifungal
activity under physiological conditions.
In vivo role of HRG
To investigate the role of HRG during Candida infection in vivo,w e
designed a mouse model of intraperitoneal infection with C. albicans.
After infection, the body weight of the mice was followed for three
days (Figure 6A). Hrg
2/2 mice showed a significantly increased
Figure 3. The antifungal activity of the histidine-rich domain of HRG is significantly increased at low pH. (A) Sequence of HRG and
synthetic peptides used in this study are indicated. (B) Screening of antifungal epitopes of HRG. 20-mer peptides spanning the whole sequence of
HRG (for sequences see Table S1) were used in radial diffusion assays against C. parapsilosis ATCC 90018 and C. albicans ATCC 90028 in 10 mM Tris,
pH 7.4 or in 10 mM MES, pH 5.5. A 4 mm diameter well was loaded with 6 ml of 100 mM peptide. The clearance zones (mm) were measured after an
overnight incubation at 27uC (n=6). (C) Comparison of the antifungal activity of rHRG and the truncated version rHRG1-240. C. parapsilosis ATCC
90018 (1610
5 cfu) was incubated with 0.6 mM rHRG or rHRG1-240 in 10 mM Tris, pH 7.4 or in 10 mM MES, pH 5.5. Samples were plated and the
number of cfu was determined. Significance was determined using Kruskall-Wallis one-way ANOVA analysis (*** p,0.001, n=6).
doi:10.1371/journal.ppat.1000116.g003
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mice, and the wild type mice regained their initial weight after three
days. Blood samples were collected from the animals 2 days post
infection,andthefungalloadinbloodwasdetermined(Figure6B).A
significantly higher amount of Candida cells was detected inthe blood
of Hrg
2/2 mice when compared with wild type mice (p=0.032),
indicating that a systemic infection has developed in HRG-deficient
mice. In a similar experiment, we determined the ability of the fungi
to establish infection in target organs distant from the site of
administration. The spleen and kidney were harvested 3 days after
initiation of intraperitoneal infection and the fungal load was
determined. The results showed significant differences between
Hrg
2/2 mice and the wild type mice; one animal out of 10 in the
control group showed fungal load in the spleens and kidneys
compared with 8 out of 10 in the Hrg
2/2 group (p=0.009)
(Figure 6C). Histopathological examination of the kidney tissues
from Hrg
2/2 mice showed dense neutrophil infiltrates and notably,
Candida cells were visualised by PAS staining in the centre of these
infiltrates (Figure 6D). These results show a striking protective role
for HRG against invasive Candida infection in vivo.
Discussion
The key findings in our study are the identification of an
antifungal activity of HRG in vivo together with the characterization
of possible epitopes of HRG mediating this effect, as well as
mechanistic data on HRG targeting of Candida membranes. The
results have implications for our understanding of novel antifungal
properties of HRG, and demonstrate that HRG constitutes a
previously undisclosed natural and antimicrobial defence system.
From a structural perspective, several lines of evidence indicate
that the HRR is, at least to a significant extent, responsible for the
HRG interaction with Candida membranes. Although the 3D
structure of HRG has not yet been determined, modelling studies
suggest that the HRR of HRG forms a polyproline (II) helical
structure with numerous histidines. At physiological pH, HRG is
net negatively charged (pI 6.45). However, due to its high content
of histidine residues (,13%), which are concentrated to the HRR,
it can acquire a positive charge by protonation [20,41], and this in
turn likely facilitates the interactions between HRG and Candida.
These results were substantiated by the finding that a region of
HRG containing the motif sequence GHHPH, was antifungal,
and that low pH enhanced this activity. The high conservation of
this sequence among vertebrates likely reflects its importance for
membrane interactions of HRG [27]. However, as evident in
Figure 3B, there are also other antifungal regions in the protein,
active irrespective of pH in the interval investigated, an
observation compatible with the antifungal activity of HRG
detected at neutral pH. It should be pointed out however, that the
peptide data do not reflect the complex structure-activity
Figure 4. Antifungal activity and fungal binding of GHH20 peptide. (A) Antifungal activity of GHH20. C. parapsilosis ATCC 90018 or C.
albicans ATCC 90028 (1610
5 cfu) were incubated with GHH20 peptide (0.03 to 6 mM) for 2 hours in 10 mM Tris, pH 7.4 (N) or 10 mM MES, pH 5.5 (#),
plated and the number of cfu determined. A representative experiment (of three) is shown. (B) Flow cytometry analysis of binding of GHH20 to
fungal membranes. C. parapsilosis (5610
7 cfu) were incubated with 20 mg TAMRA-labeled GHH20 in 10 mM Tris pH 7.4 or 10 mM MES pH 5.5. (C)
Binding of 2 mg TAMRA-labeled GHH20 peptide to C. parapsilosis ATCC 90018 and inhibition by an excess of heparin. C. parapsilosis were incubated
with TAMRA-labeled GHH20 in 10 mM MES (panel 3), pH 5.5 or the same buffer supplemented with heparin (50 mg/ml) (panel 4). The left panel shows
Nomarski images (1 and 3), whereas the right panel shows red fluorescence of peptide bound to fungi. (D) The GHH20 peptide permeabilizes
ergosterol-containing liposomes preferably at pH 6.0. 1 mM GHH20 was used (n=6).
doi:10.1371/journal.ppat.1000116.g004
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not detect any major conformational changes upon interaction
with liposomes or polysaccharides, it cannot be ruled out that
conformational changes mediated by HRR interactions with intact
fungal cells lead to the exposure of additional antimicrobial
epitopes in the molecule. Nevertheless, a recombinant and
truncated variant of HRG, lacking the histidine-rich and C-
terminal domains, was not active against Candida, pointing to the
HRR as an important, possibly the most important, effector of
HRGs antifungal effects.
Many histidine-rich AMPs are known, among these the
clavanins [36], histatins, and calprotectin [42]. We have previously
shown that the antibacterial effects in vitro of various histidine-rich
peptides, both consensus motifs and peptides derived from domain
5 of HMW kininogen [17] and from HRG [27] are enhanced at
low pH or upon addition of Zn
2+. Others have reported that the
antimicrobial activity of clavanins were substantially increased in
low pH as compared with neutral pH [36]. Furthermore, the
antimicrobial effect of histatin 5 is enhanced at low pH [43], and
histidine-rich variants of magainin, the LAH4-peptides, were
recently shown to have increased antibacterial activity in low pH
compared to neutral pH [37]. Taken together, the pH dependent
activity of HRG is thus comparable to other histidine-rich proteins
and peptides, and provides an additional link between pH sensitive
AMPs and HRG. However, contrasting to histatins, which
translocate through Candida membranes, bind mitochondria, and
induce cell death by non-lytic ATP-release [44], HRG acts directly
on fungal membranes.
Many AMPs are generated by proteolysis of larger, and non-
antimicrobial holoproteins. For example, the cathelicidin LL-37 is
released from hCAP18, and other AMPs are proteolytically
generated from complement factor C3 and high molecular weight
kininogen [3,11,12,14–17]. Considering that intact HRG is
antifungal, proteolysis of this molecule does not appear to be needed
for activity.It isofnote that likeHRG, several antimicrobialproteins
are antimicrobial per se, including bacterial permeability increasing
protein, serprocodins such as proteinase 3, elastase and heparin
binding protein, as well as lactoferrin [27,45]. However, it is also
described that antibacterial proteins, such as bacterial permeability
increasing protein and lactoferrin, may give rise to peptides exerting
antibacterial activities [46,47]. Likewise, it has been shown that
HRG may be degraded by plasmin [48], as well as in patients
undergoing thrombolytic therapy [49] and bioactive fragments of
HRG are involved in antiangiogenesis [26,41]. Thus, although a
Figure 5. Localization and activities of HRG. (A) Analysis of HRG in biological fluids. The indicated biological materials were electrophoresed on
a 8% gel (Tris-Glycine, non-reducing conditions) (left panel) or on a 16.5% Tris-Tricine gel under reducing conditions (right panel) and transferredt oa
nitrocellulose membrane. Western blot was performed using polyclonal antibodies directed against the GHH20 epitope of HRG. (B) Localization of
HRG in fibrin clots. Human control plasma (panel 4) or plasma depleted of HRG (panel 2) were incubated with FITC-labeled HRG and clots were
generated overnight after addition of 10 mM Ca
2+ at 37uC. The clots were mounted on slides and visualized by fluorescence microscopy. The left side
shows Nomarski images (1 and 3), whereas the right part shows fluorescence of HRG associated with the clots. (C) Candida growth in plasma. C.
parapsilosis (2610
7 cfu) was inoculated in human plasma (N) or human HRG-deficient plasma (#) and incubated at 27uC for 0, 4 ,8 or 18 hours and the
number of cfu was determined (n=6). (D) Antifungal activity of HRG ex vivo. Mouse control plasma or plasma of Hrg
2/2 mice were used to form
fibrin clots in the presence of 10 mM Ca
2+. Clots were incubated with C. parapsilosis ATCC 90018 (1610
5 cfu) in 10 mM MES, pH 5.5 for 2 hours,
plated and the number of cfu determined (p=0.043, n=6).
doi:10.1371/journal.ppat.1000116.g005
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wound fluid and after binding to fibrin, it is likely that degradation of
HRG may occur at sites of high proteolysis and plasmin activity.
Indeed, the finding that the HRG-derived peptide GHH20, as well
as numerous other other 20mer peptides were antifungal, and as
particularly noted for HRR-derived peptides, exhibiting a similar
pH dependence as HRG, exemplifies that the holoprotein is not a
prerequisite for antifungal action. Clearly, such possibilities need to
be addressed in future studies.
As previously mentioned, HRG is involved in various aspects of
angiogenesis, coagulation, and fibrinolysis [20], reflecting its
interactions with ligands such as heparin, plasminogen, fibrinogen,
and thrombospondin. Additionally, it acts as an opsonin by bridging
FcyRI receptors on macrophages to DNA on apoptotic cells,
stimulating phagocytosis[50],andmodulates the binding ofIgGand
immune complexes to FccRI [50]. Considering these multiple roles,
it is likely that HRG binding to microbial surfaces could
induce additional ‘‘down-stream’’ effects, such as modulation of
plasminogen activity and phagocytosis. The history of ‘‘classic’’
AMPshaveshownthatthesemolecules,initiallybelieved totakepart
merely in direct microbial killing, have extended their roles into the
ability to act as chemokines and to induce chemokine production
leading to recruitment of leukocytes, promotion of wound healing,
and an ability to modulate adaptive immunity [51]. Indeed, as
interestintheinvivofunctionsofhostdefencepeptidesisincreasing,it
is important to consider the direct antimicrobial and immunomod-
ulatory properties observed. Nevertheless, several findings in this
study unequivocally demonstrate that HRG, like many AMPs, acts
directly on microbes. Thus, in addition to the antifungal in vitro data,
the enhanced fungal growth in HRG-deficient plasma, as well as the
finding that Candida was detected at higher levelsin blood of Hrg
2/2
animals, indicates a direct antifungal action of the molecule. It is also
interesting to note that these HRG deficient animals have also been
shown to be more susceptible to Streptococcus pyogenes infection
(Shannon et al, unpublished results). However, considering both
AMP and HRG multifunctionality in vitro as well as in vivo,i tm a yb e
Figure 6. Candida produces severe infection in Hrg
2/2 mice. (A) Weight loss in mice after infection with C.albicans. C57BL/6 (solid line) and
C57BL/6 Hrg
2/2 (dotted line) mice were infected (i.p.) with 1610
9 cfu of C. albicans, and the body weight was followed from day 0 to day 3 (n=6,4
and 2, respectively) (p=0.02). (B) Fungal dissemination to the bloodstream. C57BL/6 (N) (n=4) and C57BL/6 Hrg
2/2 (#) (n=5) mice were infected as
above and the animals were sacrificed on day 2 and number of cfu in blood was determined (p=0.032). (C) HRG suppresses fungal dissemination to
the spleen and kidney. C57BL/6 (N) and C57BL/6 Hrg
2/2 (#) mice were infected as above and the cfu of C. parapsilosis in spleen and kidney was
determined (p=0.009, n=10) (D) In two animals kidneys were collected on day 3, fixed, sectioned and then stained with hematoxylin and eosin (HE)
(left panel) or PAS (right panel) (upper section; magnification 610 and lower section; magnification 630).
doi:10.1371/journal.ppat.1000116.g006
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effects, will likely be revealed. All of these effects may be dependent
on binding of HRG to microbes and subsequent interactions with
cells (e.g., neutrophils and macrophages) in different compartments
(e.g., skin, internal organs, and blood). In this respect, the pH
dependenceofHRG is particularly interesting and relevant. It is well
known that infection foci, including abscesses, are characterized by
low pH levels reaching as low as pH 5, due to increased anaerobic
metabolism and lactate production, as well as leukocyte mediated
oxidative burst and subsequent acidification [52]. The capacity of
HRG to kill Candida at these pH levels and the corresponding
increase in salt-resistance at low pH suggest that HRG could target
infection foci, resulting in a physiologically relevant concentration
and localization of antifungal activity. As previously mentioned,
HRG’s opsonising activity could hypothetically lead to enhanced
phagocytosis. Although it remains to be investigated, such
localisation of antifungal activity to endosomal compartments,
where acidification could result in enhanced HRG-mediated killing
of phagocytosed fungi, could serve as an effective way of eliminating
invadingCandidacellsatsitesoftissueinflammationwithoutreleasing
potentially toxic microbial components.
Again hypothetically, genetic deficiencies of HRG or acquired
functional defects could provide interesting clues with respect to
functional roles of HRG. In some patients, reduced levels of HRG
are associated with a thrombophilic phenotype, indeed compatible
with the phenotype observed in Hrg
2/2 mice, which had a shorter
prothrombin time [22]. As these patients still have ,20–50% of
normal levels of HRG, the human phenotype of complete absence
of HRG remains, however unknown. Although patients with low
levels of HRG have not been reported to be more prone to
infections, it must be remembered that examples from deficiencies
of particular innate immune proteins, e.g., complement and
mannose-binding lectin, illustrate that even homozygous deficien-
cy and a complete absence of a particular innate immune molecule
may give rise to surprisingly mild symptoms. For example, patients
with mannose-binding lectin deficiencies are normally not at risk
of developing infections unless compromised by immune suppres-
sion or severe disease [53]. In this context, it is particularly
interesting that antibodies against HRG have been detected in
patients with antiphospholipid syndrome [54], a disease associated
with thrombodiathesis and systemic lupus erythematosus. Notably,
the latter disease is associated with an increased risk for
opportunistic infections, including Candida [55]. Taken together,
and considering the role of HRG in innate immunity, it should be
of interest to study potential associations between functional
inactivation(s) or deficiencies of HRG as well as genetically
determined differences, in relation to the occurrence of infections.
During the last three decades, research on innate immune
molecules has demonstrated the significance of the innate immune
system for prevention of invasion by microbes at biological
boundaries. Previous studies have emphasized that various
molecules, such as ‘‘classic’’ AMPs, complement factors, and
cytokines, bridge between innate and adaptive immunity. The
present work adds another significant component to this family of
molecules, the plasma protein HRG.
Materials and Methods
Materials
The peptides GHH20 (GHHPHGHHPHGHHPHGHHPH)
and histatin 5 (DSHAKRHHGYKRKFHEKHHSHRGPY) were
synthesized by Innovagen AB (Lund, Sweden), and were of .95%
purity. The purity and molecular weight was confirmed by
MALDI-TOF MS analysis (Voyager, Applied Biosystems). 20-mer
synthetic peptides (PEP-screen) spanning the sequence of HRG
(Table 1) were obtained from Sigma-Genosys (St Louis, MO).
Polyclonal rabbit antibodies against GHH20 and TAMRA-
labeled GHH20 were from Innovagen AB (Lund, Sweden).
HRG was FITC-labeled using the FluoroTag FITC Conjugation
Kit (Sigma, St Louis, MO). Human serum and plasma were
collected from healthy volunteers. Sterile wound fluids were
obtained from surgical drainages after mastectomy. The use of
human wound fluid was approved by the Ethics Committee at
Lund University (LU 708-01). Seminal plasma was collected at the
Fertility Center at Malmo ¨ University Hospital, Sweden. The
GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html)
accession number of human histidine-rich glycoprotein is
NP_000403.
Fungal strains
The fungi Candida parapsilosis BD 17837 and Candida albicans BD
1060 were clinical isolates. C. parapsilosis ATCC 90018, C. albicans
ATCC 90028, Candida glabrata ATCC 90030, and Candida krusei
ATCC 6258 isolates were from the American Type Culture
Collection (ATCC, Rockville, MD).
Purification of human HRG
Serum HRG was purified using nickel-nitrilotriacetic acid (Ni-
NTA) agarose as described before [27]. The concentration of the
protein was determined using the Bradford method [56].
Production and purification of recombinant HRG (rHRG
and rHRG1-240)
Recombinant His-tagged HRGP and truncated version of HRG
(HRG1-240), containing amino acids 1-240 was produced and
purified as previously described [26,27].
Western blot
P l a s m a ,s e r u m ,w o u n df l u i d s ,s e m i n a lp l a s m a( 1ml), and platelets
(fluid from 1610
3 cells, disrupted by freeze thawing) were
electrophoresed on 8% SDS-polyacrylamide (SDS-PAGE) gel or an
16.5% Tris-tricine gel and transferred to a nitrocellulose membrane
(Hybond-C, GE Healthcare BioSciences, Little Chalfont, UK) [57].
The membrane was incubated in 3% skimmed milk in 10 mM Tris,
0.15 M NaCl, pH 7.4 for 1 h at room temperature, followed by
incubation for 1 h with rabbit polyclonal antibodies against GHH20
(diluted 1:1000 in the same buffer). The membrane was washed 3
times, and incubated again for 1 h with horseradish peroxidase-
conjugated secondary swine anti rabbit antibodies diluted 1:1000
(Dako, Carpinteria, CA). The image was developed using the ECL
system (Amersham Biosciences).
Preparation of fibrin clots
Human plasma was subjected to a Ni-NTA agarose gel. The
eluent (plasma completely depleted of HRG) was collected and used
to form clots. Hrg
2/2 and C57BL/6 (wild type) mice [22] were used
for preparation of fibrin clots from plasma of the respective animals.
Plasma deficient of HRG and normal plasma were incubated with a
total concentration of 10 mM Ca
2+ in eppendorf tubes at 37uCo v e r
night. Clots were washed three times and then stored in 10 mM 2-
Morpholinoethanesulfonic acid (MES), pH 5.5. Clots (,0.04g) were
used in viable count experiments. To investigate the localization of
HRG infibrinclots,human plasmaandHRG-deficientplasma were
incubated with 10 ml FITC-labeled HRG (0.4 mg/ml) and then
processed as before in the presence of 10 mM Ca
2+ over night. The
clots werethenwashed indistilled waterand mountedonslidesusing
Dako mounting media (Dako).
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C. parapsilosis, C. albicans, C. glabrata and C. krusei were grown to
mid-logarithmic phase in Todd-Hewitt (TH) medium (Becton and
Dickinson, Maryland, USA) at 27uC and washed in 10 mM Tris,
pH 7.4 or 10 mM MES, pH 5.5. For dose-response experiments,
purified HRG or GHH20 (0.03–6 mM) were incubated with
1610
5 C. parapsilosis ATCC 90018 or C. albicans ATCC 90028 for
2 h at 37uC in 10 mM, Tris, pH 7.4 or in 10 mM MES-buffer,
pH 5.5, plated on Sabouraud dextrose broth (Becton and
Dickinson) agar, and incubated 48 hours at 27uC, whereafter
the number of cfu was determined. In order to investigate the
antifungal activity of HRG in presence of salt, 6 mM HRG were
incubated with 1610
5 C. parapsilosis ATCC 90018 for 2 h at 37uC
in 10 mM, MES, pH 5.5 containing 0, 25, 50, 100 or 150 mM
NaCl, plated and the number of cfu was determined. In kinetic
experiments, 0.3 and 3 mM HRG were incubated with C.
parapsilosis ATCC 90018 for 5, 15, 30, 60, or 120 minutes in
10 mM MES, pH 5.5, plated and the number of cfu was
determined. For determination of the effect of HRG on various
Candida strains, HRG (3 mM) was incubated with C. parapsilosis
ATCC 90018 or BD 17837, C. albicans ATCC 90028 or BD 1060,
C. glabrata ATCC 90030 or C. krusei ATCC 6258 in 10 mM Tris,
pH 7.4 or 10 mM MES, pH 5.5, plated and number of cfu
determined. Truncated and full length recombinant HRG, 0.6
mM rHRG, or rHRG1-240 were incubated with C. parapsilosis
(1610
5) for two hours and then plated and number of cfu
determined. To investigate the in vitro antifungal activity of HRG,
normal or HRG-deficient fibrin clots (,0.04g) were incubated
with C. parapsilosis ATCC 90018 for 2 h in 10 mM MES, pH 5.5,
plated and number of cfu were determined. For inhibition studies,
0.3 mM HRGP were incubated with C. parapsilosis (1610
5)i n
10 mM MES, pH 5.5, in presence or absence of heparin (50 mg)
for two hours and then plated and number of cfu was determined.
In all experiments, 100% survival was defined as total survival of
fungi in the same buffer and under the same conditions in absence
of peptide, protein, or clots. The p-values were determined using
Kruskall-Wallis one-way ANOVA analysis.
Radial diffusion assay
Radial diffusion assay (RDA) was performed essentially as
described earlier [58]. C. parapsilosis ATCC 90018 and C. albicans
ATCC 90028 were grown to midlogarithmic phase in TH-medium,
and then washed with distilled water. 4610
6colonyformingunitswas
added to 5 ml of the underlay agarosegel (0.03% (w/v) trypticase soy
broth (TSB), 1% (w/v) low electroendosmosis type agarose (Sigma),
0.02% (v/v) Tween 20 (Sigma). The buffers used in the underlay gels
were 10 mM Tris, pH 7.4 or 10 mM MES, pH 5.5. The underlay
gel was poured into an 85-mm Petri dish. After agarose solidification,
wells of 4 mm in diameter were punched, and 6 ml of peptide solution
wasaddedtoeachwell.Bufferswereusedasanegativecontrol.Plates
were incubated at 28uC for 3 h to allow diffusion of the peptides. The
underlay gel was then covered with 5 ml of molten overlay.
Antimicrobial activity of a peptide isv i s u a l i z e da saz o n eo fc l e a r a n c e
around each well after 18–24 h of incubation at 28uC. Peptides were
tested in concentrations of 100 mM.
Binding of HRG to Candida
C. parapsilosis (1610
5 cfu) were incubated with 0.6 mM HRG in
50 ml 10 mM MES, pH 5.5, with or without heparin (50 mg/ml)
for 2 h at 37uC, centrifuged and the pellet was washed three times
in 10 mM MES, pH 5.5. The pellet and the supernatant were
resuspended in SDS sample buffer, electrophoresed (8% SDS-
PAGE), and then transferred to a nitrocellulose membrane.
Western blotting was performed as above.
Fluorescence microscopy
C. parapsilosis ATCC 90018 fungi were grown in TH medium at
27uC to mid-logarithmic phase. The fungi were washed in 10 mM
Tris, pH 7.4, and resuspended in the same buffer. C. parapsilosis
(2610
6/ ml) were incubated with 1 ml of TAMRA-labeled
GHH20 (2 mg/ml) in 10 mM MES, pH 5.5, with or without
heparin (50 mg/ml), left standing for 5 minutes on ice, and then
washed twice in 10 mM Tris, pH 7.4. Fungi were fixed with 4%
paraformaldehyde by incubation on ice for 15 minutes and in
room temperature for 45 minutes. The fungi were then applied
onto Poly-L-lysine coated cover glass and after an incubation time
of 30 minutes, finally mounted on slides using Dako mounting
media (Dako, Carpinteria, CA). In order to assess permeabilisa-
tion, C. albicans ATCC 90028 (2610
6 cfu) were incubated with
HRG or LL-37 (both at 10 mM) in 10 mM Tris, pH 7.4 or 10 mM
MES, pH 5.5 for 30 minutes at 37uC. Samples were transferred to
Poly-L-lysine coated cover glass and incubated for 45 minutes at
37uC, washed and 2 mg of FITC were added in a volume of 200
ml, and incubated for 30 minutes at 30uC, washed and then fixed
as above. Samples were visualized using a Nikon Eclipse TE300
inverted fluorescence microscope equipped with a Hamamatsu
C4742-95 cooled CCD camera, a Plan Apochromat 100X
objective and a high N.A. oil condenser.
Negative staining and transmission electron microscopy
C. parapsilosis ATCC 90018 were grown in TH medium at 37uC
to mid-logarithmic phase. The fungi were washed in 10 mM Tris,
pH 7.4 or 10 mM MES, pH 5.5, and resuspended in the same
buffer. HRG or LL-37 (10 mM) was incubated with C. parapsilosis
(20610
6 cfu) for two hours in a total volume of 10 ml in Tris buffer,
pH 7.4 or in MES buffer, pH 5.5. Samples of C. parapsilosis fungi
suspensions were adsorbed onto carbon-coated copper grids for
1 min, washed briefly on two drops of water, and negatively
stained on two drops of 0.75 % uranyl formate. The grids were
rendered hydrophilic by glow discharge at low pressure in air.
Specimens were observed in a Jeol JEM 1230 electron microscope
operated at 60 kV accelerating voltage. Images were recorded
with a Gatan Multiscan 791 CCD camera.
Flow cytometry
C. parapsilosis ATCC 90018 were grown in TH medium at 27uC
to mid-logarithmic phase. The fungi were washed in 10 mM Tris,
pH 7.4 or 10 mM MES, pH 5.5 and resuspended in the same
buffer. C. parapsilosis (5610
7 in a total volume of 0.5 ml) were
incubated with 10 ml of FITC-labeled HRG (0.4 mg/ml) or 10 ml
TAMRA-labeled GHH20 (2 mg/ml) in 10 mM Tris, pH 7.4 or in
10 mM MES, pH 5.5, let stand for 5 minutes on ice and then
washed in 10 mM Tris, pH 7.4. The cells were fixed with 4%
paraformaldehyde by incubation on ice for 15 minutes and in room
temperature for 45 minutes. Flow cytometry analysis was performed
using a FACS-Calibur flow cytometry equipped with a 15 mW
argon laser turned a 488 mm (Becton-Dickinson, Franklin Lakes,
NJ). The fungal population was selected by gating with appropriate
settings of forward scatter (FSC) and sideward scatter (SSC). The
FL1 fluorescence channel (lem=530 nm) was used to record the
emitted fluorescence of FITC, and the FL3 fluorescence channel
(lem=585 nm) was used to recordthe emitted fluorescenceof Texas
red.
Liposome preparation and leakage assay
Dry lipid films were prepared by dissolving dioleoylphosphati-
dylcholine (1,2-dioleoyl-sn-Glycero-3-phoshocholine, .99% purity,
Avanti Polar Lipids, Alabaster, AL) (60 mol%) and either ergosterol
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and then removing the solvent by evaporation under vacuum
overnight. Subsequently, buffer (10 mM Tris, pH 7.4) was added
together with 0.1 M carboxyfluorescein (CF) (Sigma, St Louis, MO).
After hydration, the lipid mixture was subjected to eight freeze-thaw
cycles consisting of freezing in liquid nitrogen and heating to 60uC.
Unilamellar liposomes, of about Ø140 nm were generated by
multiple extrusions through polycarbonate filters (pore size 100 nm)
mounted in a LipoFast miniextruder (Avestin, Ottawa, Canada) at
22uC. Untrapped CF was then removed by two gel filtrations
(Sephadex G-50) at 22uC, with Tris buffer as eluent. CF release was
determined by monitoring the emitted fluorescence at 520 nm from
liposome dispersions (10 mM lipid in 10 mM Tris). An absolute
leakage scale was obtained by disrupting the liposomes at the end of
the experiment through addition of 0.8 mMTriton X100 (Sigma, St
Louis, MO), causing 100% release and dequenching of CF.
Although calcein is frequently used for pH-dependent leakage
studies, the high charge of this dye has been noted to influence its
leakage behaviour in the presence of highly cationic peptides [59].
Instead, therefore, CF was used as a leakage marker at both pH 6.0
and 7.4, however, avoiding pH-dependent fluorescence effects
through neutralization prior to probing the limiting leakage in case
of pH 6.0 leakage. Throughout, a SPEX-fluorolog 1650 0.22-m
double spectrometer (SPEX Industries, Edison, NJ) was used for the
liposome leakage assay. Measurements were performed at 37uC.
CD spectroscopy
The CD spectra of the peptides in solution were measured on a
Jasco J-810 Spectropolarimeter (Jasco, U.K.). Measurements were
performed at 37uC in a 10 mm quartz cuvet under stirring and the
effect on protein/peptide secondary structure monitored in the
range 200–260 nm. The background value, detected at 250 nm,
was subtracted, and signals from the bulk solution were corrected
for. The secondary structure was monitored at a concentration of
0.25 mM of HRG in buffer, in the presence of liposomes (lipid
concentration 100 mM), and in the presence of mannan from
Saccharomyces cerevisiae (0.02 wt%; Sigma-Aldrich, St. Luis, USA).
Fungal growth in plasma
C. parapsilosis ATCC 90018 were grown in TH medium at 27uC
to mid-logarithmic phase. The fungi were washed in 10 mM
MES, pH 5.5 and resuspended in the same buffer. C. parapsilosis
(2610
7) cfu in a total volume of 10 ml was added to 50 ml of human
normal plasma or HRG-depleted plasma (eluent from Ni-NTA
agarose gel), and incubated for 0, 4, 8 or 18 hours at 27uC and
then plated and number of cfu determined.
Animal experiments
The original knockout mice 129/B6-HRG
tm1wja1 were crossed
with C57BL/6 mice (Taconic) for 14 generations to obtain
uniform genetic background. These HRG-deficient mouse strain
was called B6-HRG
tm1wja1 following ILAR (Institute of Laboratory
Animal Resources) rules. Wildtype C57BL/6 control mice and
C57BL/6 Hrg
2/2 mice (8–12 weeks, 27+/24g) were bred in the
animal facility at Lund University. C57BL/6 Hrg
2/2, lacks the
translation start point of exon 1 of the Hrg gene [22]. Animals
were housed under standard conditions of light and temperature
and had free access to standard laboratory chow and water. In
order to study Candida dissemination, C. albicans ATCC 90018
were grown to midlogarithmic phase, washed and diluted in PBS,
pH 7.4. Two hundred and fifty ml containing 1610
9 cfu was
injected intraperitoneally into C57BL/6 or C57BL/6 Hrg
2/2
mice, divided into weight and sex matched groups. The animals
were sacrificed 48 hours post infection, and blood was collected by
cardiac puncture. The number of cfu was determined by viable
count. In order to study fungal dissemination to target organs, the
mice were infected as previously described and three days later the
spleen and kidney were harvested on ice.
Histology
Representative animals were sacrificed three days post infection
and the kidneys were removed into 4% formalin. The tissues were
embedded in paraffin, sectioned and stained with Hematoxylin
and eosin (H&E) and with Periodic acid-Schiff (PAS).
Supporting Information
Table S1 Synthetic 20-mer peptides spanning the whole
sequence of HRG, used in the screening of antifungal activity in
Figure 3B, and relevant descriptive parameters (net charge,
activity against C. albicans and C. parapsilosis, content (%) of the
basic amino acids K, R, H, and the acidic D, E.
Found at: doi:10.1371/journal.ppat.1000116.s001 (0.07 MB
DOC)
Figure S1 Correlation between net charge and antifungal
activity. 20-mer peptides spanning the whole sequence of HRG
(for sequences see Table S1) were used in radial diffusion assay
against C. albicans ATCC 90028 in 10 mM Tris, pH 7.4 (N)o ri n
10 mM MES, pH 5.5 (#). A 4 mm diameter well was loaded with
6 ml of 100 mM peptide. The clearance zones (mm) were measured
after an overnight incubation at 27uC. The equation for the line of
regression is y=0.605x + 1.222 for peptides in pH 7.4 and
y=0.543x + 0.662 for pH 5.5.
Found at: doi:10.1371/journal.ppat.1000116.s002 (31.73 MB
TIF)
Figure S2 Inhibition of antifungal activity by heparin. 0.3 mM
HRG were incubated with 1610
5 cfu C. parapsilosis ATCC 90018
in 10 mM MES, pH 5.5 with or without 50 mg heparin, plated
and the number of cfu determined (n=6).
Found at: doi:10.1371/journal.ppat.1000116.s003 (1.16 MB TIF)
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